Savara Inc. (SVRA) – Market Performance
- Price movement: Down 1.89 % to USD 4.73 at 03:55 PM Central Europe, Thursday 22 Oct 2026.
- Shares outstanding: 254.2 million.
- Market capitalization: USD 1.20 billion.
- 24‑hour trading volume: USD 9.70 million.
- Month‑to‑date change: Down 11.89 % since the previous month‑end.
- 200‑day simple moving average: USD 5.43.
- 52‑week range: Highest USD 7.00 on 12 Dec 2025; lowest USD 3.86 on 07 Nov 2025.
Latest Scientific Update
Savara Inc. presented subgroup data from its Phase 2/3 IMPALA trial at the CHEST 2026 Annual Meeting. The analysis focused on patients with autoimmune pulmonary alveolar proteinosis (aPAP) who maintained relatively preserved diffusing capacity. Key findings:
- Daily inhaled molgramostim was associated with measurable improvements in lung gas transfer, reduced pulmonary surfactant burden, and better quality‑of‑life scores compared with placebo.
- The results are exploratory due to a limited sample size but align with earlier Phase 3 outcomes.
- The data suggest potential benefit of molgramostim across a spectrum of disease severity.
Savara remains in the clinical development stage; its lead product molgramostim is in Phase 3. The company continues to monitor safety and efficacy within its broader rare‑disease pipeline.
Comparative 24‑Hour Performance of Related Stocks
| Ticker | Price change (24 h) | Current price | Market cap (USD bn) | P/E ratio |
|---|---|---|---|---|
| ESQ | –0.41 % | USD 120.00 | 1.40 | 19.6 |
| KEEL | +2.56 % | USD 2.38 | 1.50 | – |
| HLF | –0.44 % | USD 13.93 | 1.40 | 8.89 |
| PCRX | –0.14 % | USD 36.38 | 1.50 | 103.33 |
| PNTG | –1.06 % | USD 41.59 | 1.50 | 45.74 |
Notes on Keel Infrastructure (KEEL)
- Two short‑position filings dated 21 Oct 2026 reported net short positions by Arrowstreet Capital, Limited Partnership (14 Jul 2026) and Davidson Kempner Capital Management LP (22 Jul 2026).
- The filings describe the positions as a small portion of issued share capital and do not indicate an immediate impact on the company’s financial outlook.
Pacira Biosciences (PCRX) Corporate Highlights
- Partnership with the National Institutes of Health for therapeutic protein delivery research.
- Strategic investment from a leading venture capital firm to expand bioprocessing capabilities.
- Announced a new clinical trial plan for a next‑generation antibody drug.
- Reported sufficient liquidity to support ongoing operations and planned clinical activities.
Company Overview – Savara Inc.
Savara Inc. is a clinical‑stage pharmaceutical company focused on developing novel therapies for rare respiratory diseases that can be life‑threatening. The company operates globally and applies biotechnology expertise to address serious respiratory conditions.
